Agilent Technologies, Inc. (0HAV.L)
USD 136.25
(-0.67%)
USD 136.25
(-0.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.24 Billion USD | -1.12% |
| 2022 | 1.25 Billion USD | 3.64% |
| 2021 | 1.21 Billion USD | 68.29% |
| 2020 | 719 Million USD | -32.87% |
| 2019 | 1.07 Billion USD | 238.92% |
| 2018 | 316 Million USD | -53.8% |
| 2017 | 684 Million USD | 48.7% |
| 2016 | 460 Million USD | 15.58% |
| 2015 | 398 Million USD | -19.92% |
| 2014 | 497 Million USD | -31.35% |
| 2013 | 724 Million USD | -37.21% |
| 2012 | 1.15 Billion USD | 13.93% |
| 2011 | 1.01 Billion USD | 62.18% |
| 2010 | 624 Million USD | 2112.9% |
| 2009 | -31 Million USD | -104.47% |
| 2008 | 693 Million USD | 8.62% |
| 2007 | 638 Million USD | -80.71% |
| 2006 | 3.3 Billion USD | 911.31% |
| 2005 | 327 Million USD | -6.3% |
| 2004 | 349 Million USD | 116.96% |
| 2003 | -2.05 Billion USD | -99.42% |
| 2002 | -1.03 Billion USD | -714.29% |
| 2001 | 168 Million USD | -77.81% |
| 2000 | 757 Million USD | 47.85% |
| 1999 | 512 Million USD | 99.22% |
| 1998 | 257 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 308 Million USD | -11.49% |
| 2024 Q3 | 282 Million USD | -8.44% |
| 2024 Q1 | 348 Million USD | -26.74% |
| 2023 FY | 1.24 Billion USD | -1.12% |
| 2023 Q3 | 111 Million USD | -63.25% |
| 2023 Q1 | 352 Million USD | -4.35% |
| 2023 Q2 | 302 Million USD | -14.2% |
| 2023 Q4 | 475 Million USD | 327.93% |
| 2022 Q1 | 283 Million USD | -35.97% |
| 2022 Q3 | 329 Million USD | 20.07% |
| 2022 FY | 1.25 Billion USD | 3.64% |
| 2022 Q4 | 368 Million USD | 11.85% |
| 2022 Q2 | 274 Million USD | -3.18% |
| 2021 Q4 | 442 Million USD | 67.42% |
| 2021 Q1 | 288 Million USD | 29.73% |
| 2021 Q2 | 216 Million USD | -25.0% |
| 2021 Q3 | 264 Million USD | 22.22% |
| 2021 FY | 1.21 Billion USD | 68.29% |
| 2020 Q2 | 101 Million USD | -48.73% |
| 2020 Q4 | 222 Million USD | 11.56% |
| 2020 FY | 719 Million USD | -32.87% |
| 2020 Q3 | 199 Million USD | 97.03% |
| 2020 Q1 | 197 Million USD | 1.55% |
| 2019 FY | 1.07 Billion USD | 238.92% |
| 2019 Q4 | 194 Million USD | 1.57% |
| 2019 Q3 | 191 Million USD | 4.95% |
| 2019 Q2 | 182 Million USD | -63.89% |
| 2019 Q1 | 504 Million USD | 158.46% |
| 2018 Q4 | 195 Million USD | -17.37% |
| 2018 Q1 | -320 Million USD | -280.79% |
| 2018 Q3 | 236 Million USD | 15.12% |
| 2018 Q2 | 205 Million USD | 164.06% |
| 2018 FY | 316 Million USD | -53.8% |
| 2017 Q1 | 168 Million USD | 35.48% |
| 2017 Q4 | 177 Million USD | 1.14% |
| 2017 Q3 | 175 Million USD | 6.71% |
| 2017 FY | 684 Million USD | 48.7% |
| 2017 Q2 | 164 Million USD | -2.38% |
| 2016 FY | 460 Million USD | 15.58% |
| 2016 Q4 | 124 Million USD | 0.0% |
| 2016 Q2 | 91 Million USD | -26.02% |
| 2016 Q1 | 123 Million USD | -12.14% |
| 2016 Q3 | 124 Million USD | 36.26% |
| 2015 Q4 | 140 Million USD | 35.92% |
| 2015 Q2 | 83 Million USD | 15.28% |
| 2015 Q1 | 72 Million USD | 350.0% |
| 2015 FY | 398 Million USD | -19.92% |
| 2015 Q3 | 103 Million USD | 24.1% |
| 2014 FY | 497 Million USD | -31.35% |
| 2014 Q3 | 147 Million USD | -2.0% |
| 2014 Q4 | 16 Million USD | -89.12% |
| 2014 Q1 | 195 Million USD | -7.58% |
| 2014 Q2 | 150 Million USD | -23.08% |
| 2013 FY | 724 Million USD | -37.21% |
| 2013 Q2 | 166 Million USD | -7.26% |
| 2013 Q3 | 168 Million USD | 1.2% |
| 2013 Q4 | 211 Million USD | 25.6% |
| 2013 Q1 | 179 Million USD | -57.88% |
| 2012 FY | 1.15 Billion USD | 13.93% |
| 2012 Q4 | 425 Million USD | 74.9% |
| 2012 Q3 | 243 Million USD | -4.71% |
| 2012 Q2 | 255 Million USD | 10.87% |
| 2012 Q1 | 230 Million USD | -20.42% |
| 2011 FY | 1.01 Billion USD | 62.18% |
| 2011 Q3 | 330 Million USD | 65.0% |
| 2011 Q1 | 193 Million USD | -33.9% |
| 2011 Q2 | 200 Million USD | 3.63% |
| 2011 Q4 | 289 Million USD | -12.42% |
| 2010 Q4 | 292 Million USD | 42.44% |
| 2010 Q3 | 205 Million USD | 89.81% |
| 2010 Q2 | 108 Million USD | 36.71% |
| 2010 FY | 624 Million USD | 2112.9% |
| 2010 Q1 | 79 Million USD | 216.0% |
| 2009 Q4 | 25 Million USD | 231.58% |
| 2009 FY | -31 Million USD | -104.47% |
| 2009 Q1 | 64 Million USD | -72.29% |
| 2009 Q2 | -101 Million USD | -257.81% |
| 2009 Q3 | -19 Million USD | 81.19% |
| 2008 FY | 693 Million USD | 8.62% |
| 2008 Q1 | 120 Million USD | -33.33% |
| 2008 Q3 | 169 Million USD | -2.31% |
| 2008 Q2 | 173 Million USD | 44.17% |
| 2008 Q4 | 231 Million USD | 36.69% |
| 2007 Q2 | 123 Million USD | -18.0% |
| 2007 Q4 | 180 Million USD | -2.7% |
| 2007 Q3 | 185 Million USD | 50.41% |
| 2007 Q1 | 150 Million USD | 0.67% |
| 2007 FY | 638 Million USD | -80.71% |
| 2006 Q2 | 115 Million USD | -95.92% |
| 2006 Q3 | 227 Million USD | 97.39% |
| 2006 Q4 | 149 Million USD | -34.36% |
| 2006 FY | 3.3 Billion USD | 911.31% |
| 2006 Q1 | 2.81 Billion USD | 11164.0% |
| 2005 Q3 | 104 Million USD | 9.47% |
| 2005 Q4 | 25 Million USD | -75.96% |
| 2005 FY | 327 Million USD | -6.3% |
| 2005 Q1 | 103 Million USD | 39.19% |
| 2005 Q2 | 95 Million USD | -7.77% |
| 2004 Q4 | 74 Million USD | -26.0% |
| 2004 Q3 | 100 Million USD | -3.85% |
| 2004 Q1 | 71 Million USD | 446.15% |
| 2004 FY | 349 Million USD | 116.96% |
| 2004 Q2 | 104 Million USD | 46.48% |
| 2003 Q1 | -369 Million USD | -56.36% |
| 2003 FY | -2.05 Billion USD | -99.42% |
| 2003 Q4 | 13 Million USD | 100.84% |
| 2003 Q3 | -1.55 Billion USD | -965.75% |
| 2003 Q2 | -146 Million USD | 60.43% |
| 2002 FY | -1.03 Billion USD | -714.29% |
| 2002 Q4 | -236 Million USD | -3.51% |
| 2002 Q3 | -228 Million USD | 9.88% |
| 2002 Q2 | -253 Million USD | 19.68% |
| 2002 Q1 | -315 Million USD | -329.93% |
| 2001 Q1 | 154 Million USD | -49.51% |
| 2001 Q4 | 137 Million USD | 162.56% |
| 2001 Q3 | -219 Million USD | -328.13% |
| 2001 Q2 | 96 Million USD | -37.66% |
| 2001 FY | 168 Million USD | -77.81% |
| 2000 Q3 | 155 Million USD | -6.63% |
| 2000 Q1 | 131 Million USD | -10.27% |
| 2000 FY | 757 Million USD | 47.85% |
| 2000 Q2 | 166 Million USD | 26.72% |
| 2000 Q4 | 305 Million USD | 96.77% |
| 1999 Q4 | 146 Million USD | 8.15% |
| 1999 Q3 | 135 Million USD | -14.01% |
| 1999 FY | 512 Million USD | 99.22% |
| 1999 Q2 | 157 Million USD | 112.16% |
| 1999 Q1 | 74 Million USD | 0.0% |
| 1998 FY | 257 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 909.299% |
| Dynavax Technologies Corporation | -6.38 Million USD | 19508.358% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -94124.924% |
| Perrigo Company plc | -12.7 Million USD | 9863.78% |
| Illumina, Inc. | -1.16 Billion USD | 206.804% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 79.316% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 379.256% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 114.358% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 8.689% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 1221.573% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 68.636% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 3210.888% |
| Waters Corporation | 642.23 Million USD | -93.076% |
| Biogen Inc. | 1.16 Billion USD | -6.795% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 580.935% |
| Evolus, Inc. | -61.68 Million USD | 2110.213% |
| Adicet Bio, Inc. | -142.65 Million USD | 969.212% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 1146.299% |
| bluebird bio, Inc. | -211.91 Million USD | 685.146% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 692.598% |
| FibroGen, Inc. | -284.23 Million USD | 536.263% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 2880.062% |
| Homology Medicines, Inc. | -53.74 Million USD | 2407.277% |
| Geron Corporation | -184.12 Million USD | 773.448% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 381.663% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 918.028% |
| Myriad Genetics, Inc. | -112 Million USD | 1207.143% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 1543.623% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 357.693% |
| Zoetis Inc. | 2.34 Billion USD | 47.099% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 2388.33% |
| Mettler-Toledo International Inc. | 788.77 Million USD | -57.205% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -639.658% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 65.742% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 3038.458% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 438.533% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 549.07% |
| Verastem, Inc. | -87.36 Million USD | 1519.3% |
| Nektar Therapeutics | -276.05 Million USD | 549.184% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 618.312% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 1501.431% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 331.353% |
| OPKO Health, Inc. | -188.86 Million USD | 756.561% |
| Exelixis, Inc. | 207.76 Million USD | -496.828% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -396.596% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -1068.268% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 2710.252% |
| uniQure N.V. | -308.47 Million USD | 501.974% |
| Imunon, Inc. | -19.51 Million USD | 6454.094% |
| Blueprint Medicines Corporation | -506.98 Million USD | 344.584% |
| Insmed Incorporated | -749.56 Million USD | 265.429% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -340.35% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 452.185% |
| TG Therapeutics, Inc. | 12.67 Million USD | -9685.354% |
| Incyte Corporation | 597.59 Million USD | -107.497% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 263.051% |